J&J Innovative Medicine Unit Shines Again in Q2: Will This Continue?

Key Takeaways JNJ's Innovative Medicine segment grew 4.9% in Q2, reaching $15.2B in sales despite Stelara headwinds.Growth was driven by Darzalex, Tremfya, Erleada and new drugs like Carvykti, Tecvayli and Talvey.JNJ expects stronger second-half growth and projects over $57B in Innovative Medicines sales for 2025.Johnson & Johnson’s (JNJ) Innovative Medicine segment markets several multi-million-dollar drugs that cover a broad range of areas, including neuroscience, cardiovascular and metabolism, immunology ...